Menu

Survodutide: The Dual Agonist Whose Best Case Is Not Weight

By Evan Marsh, EditorUpdated Sources: SYNCHRONIZE Phase 3 program and Phase 2 MASH trial

Survodutide is the compound that complicates the tidy story about receptor counting. The usual logic says more receptors means more weight loss: one for semaglutide, two for tirzepatide, three for retatrutide, numbers rising accordingly. Survodutide targets two receptors and produced less weight reduction than single-receptor semaglutide. Understanding why is more useful than any ranking.

What it is

Survodutide (BI 456906) is a dual agonist at the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim. Note which two receptors: it shares the glucagon component with retatrutide but skips GIP, wheretirzepatide takes the opposite approach and skips glucagon. It is a once-weekly subcutaneous injection, currently in Phase 3 and approved nowhere.

The weight data

Phase 3 — SYNCHRONIZE-1

725 adults randomized to 3.6 mg, 6.0 mg or placebo for 76 weeks, published in theNew England Journal of Medicine:

GroupWeight change at 76 weeks95% CI
Survodutide 3.6 mg−12.2%−13.6 to −10.8
Survodutide 6.0 mg−13.0%−14.4 to −11.6
Placebo−5.4%−6.9 to −4.0

Two details worth pausing on. The two active doses were close together — 0.8 percentage points apart — which suggests the curve had largely flattened by 3.6 mg. And the placebo arm lost 5.4%, an unusually large placebo response that narrows the placebo-adjusted difference to roughly 7.6 points.

Phase 2 — the dose-response

DoseWeight change at 46 weeks
Placebo−2.8%
0.6 mg−6.2%
2.4 mg−12.5%
3.6 mg−13.2%
4.8 mg−14.9%

The Phase 2 trial had a 60% completion rate, which is low and matters when reading the per-dose figures.

How this ranks, honestly. On the count-everyone analysis this site uses throughout, survodutide's −13.0% sits below semaglutide's −14.9%, tirzepatide's −20.9%, CagriSema's −20.4% and retatrutide's −25.0%. A dual agonist finishing behind a single-receptor drug is a genuine finding, not a rounding error — adding glucagon agonism does not automatically add weight loss, and the receptor-counting heuristic breaks here. See the full class comparison.

Where survodutide actually looks strong: the liver

The glucagon component mobilizes hepatic fat, and this is where the compound's evidence is most impressive relative to its competitors. The Phase 2 MASH trial enrolled 293 participants for 48 weeks with biopsy-confirmed endpoints:

  • 62% of the 4.8 mg group achieved improvement in metabolic dysfunction-associated steatohepatitis without worsening of fibrosis, against 14% on placebo.
  • The dose-response was quadratic, not linear — 6.0 mg performed worse (43%) than 4.8 mg, and 2.4 mg reached 47%. More is not better here, which is unusual and clinically important.
  • Gastrointestinal effects were substantial: nausea in 66% and diarrhea in 49%, against 23% each on placebo.

That result has been followed by a Phase 3 program in steatotic liver disease (SYNCHRONIZE-MASLD, reported in Nature Medicine) and a dedicated pharmacokinetics and tolerability study in cirrhosis. Read together, the development program looks less like a weight-loss drug that also helps the liver and more like a liver drug that also reduces weight.

Tolerability

The adverse-event picture is the class profile with the volume turned up: nausea and diarrhea dominate, and the MASH trial's rates (66% and 49%) are high even by incretin standards. The Phase 2 obesity trial's 60% completion rate points the same direction. Whether the newer, slower Phase 3 escalation schedules improve on that is a fair question the published data does not fully answer yet.

What is still unknown

  • No approval anywhere, and no cardiovascular or other hard-outcome data.
  • No head-to-head trial against tirzepatide, retatrutide or CagriSema in obesity.
  • Whether the MASH result holds in the larger Phase 3 program with regulatory-grade endpoints.
  • Long-term safety beyond the trial windows, and what happens after discontinuation — no published data.

Research on Survodutide

8 records in our research database, classified by evidence type:

Browse all Survodutide research →

Frequently asked questions

What is survodutide?

Survodutide (development code BI 456906) is a glucagon and GLP-1 receptor dual agonist developed by Boehringer Ingelheim. It is a once-weekly subcutaneous injection in Phase 3 trials for obesity and for metabolic liver disease. It is not approved anywhere.

How much weight does survodutide produce?

In the Phase 3 SYNCHRONIZE-1 trial, 76 weeks produced −12.2% at 3.6 mg and −13.0% at 6.0 mg on the treatment-regimen estimand, against −5.4% for placebo. That is the lowest figure among the new-generation agonists, and lower than approved semaglutide at 14.9%.

Survodutide vs retatrutide — what is the difference?

Both use glucagon receptor agonism, but retatrutide adds GIP as a third target and survodutide does not. In their respective Phase 3 obesity trials retatrutide reported roughly twice the weight reduction. Neither is approved.

What is survodutide best at?

On the published evidence, liver disease rather than weight. Its Phase 2 MASH trial reported that 62% of the 4.8 mg group achieved improvement in steatohepatitis without worsening fibrosis, against 14% on placebo — a biopsy-confirmed result that is stronger relative to its competitors than its weight numbers are.

Is survodutide available to buy?

It has no approval and no prescription pathway, and it is far less common on the research-chemical market than retatrutide or tirzepatide. Clinical trial enrollment is the only supervised access.

Sources

  • le Roux CW, Wharton S, Startseva E, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity (SYNCHRONIZE-1). New England Journal of Medicine, published online 7 June 2026. PubMed · doi:10.1056/NEJMoa2600751
  • le Roux CW et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology, 2024;12(3):162–173. PubMed
  • Sanyal AJ et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. New England Journal of Medicine, 2024. PubMed
  • Kaplan LM et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease (SYNCHRONIZE-MASLD). Nature Medicine, 2026. PubMed
  • Wharton S et al. SYNCHRONIZE-2: survodutide in adults with obesity and type 2 diabetes. Diabetes, Obesity and Metabolism, 2026. PubMed
  • Lawitz EJ et al. Efficacy, tolerability and pharmacokinetics of survodutide in cirrhosis. Journal of Hepatology, 2024. PubMed
  • Blüher M et al. Survodutide in type 2 diabetes, with a semaglutide comparator. Diabetologia, 2024. PubMed

Related guides

Research use only. Survodutide is investigational and not approved for human use anywhere. This page summarizes published trial data and is not medical advice.